A multicentre, randomised, comparative trial to assess the tolerance (maximum well-tolerated dose), efficacy and pharmacokinetics of escalating doses of CASODEX (300 mg po daily, increasing by 150 mg intervals) versus castration (medical or surgical) in the treatment of advanced carcinoma of the prostate

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].